Premium
Cognitive and biological characteristics of stage 2 of AD in the clinical multicenter DELCODE Study
Author(s) -
Jessen Frank,
Boecker Henning,
Buerger Katharina,
Heneka Michael T.,
Laske Christoph,
Peters Oliver,
Perneczky Robert,
Priller Josef,
Schneider Anja,
Spottke Annika,
Teipel Stefan J.,
Wiltfang Jens,
Wagner Michael,
Düzel Emrah
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.040265
Subject(s) - dementia , cognition , stage (stratigraphy) , medicine , neuroimaging , clinical trial , biomarker , alzheimer's disease neuroimaging initiative , disease , memory clinic , cognitive decline , longitudinal study , magnetic resonance imaging , psychology , psychiatry , pathology , radiology , paleontology , biochemistry , chemistry , biology
Background Stage 2 of Alzheimer’s disease holds particular promise for early treatment, because of largely preserved cognitive functioning. Also individuals at stage 2 may contact the medical system due to subjective cognitive (SCD) and potentially mild behavioral symptoms. Current research focuses on the refined symptomatic and biological characterization of stage 2 and the longitudinal cognitive course from stage 2 onwards. Method The DZNE (German Center for Neurodegenerative Diseases)‐Longitudinal Cognitive Impairment and Dementia Study (DELCODE) is a memory clinic based project, which enrolled 1078 participants of which 420 were patients with SCD. Extended clinical, cognitive, biomarker and neuroimaging assessments at baseline were performed. Annual follow‐up is ongoing with some having reached the fifth year of observation. Result Participants with SCD showed lower concentration of Aß42 in the cerebrospinal fluid and a higher rate of cut‐off‐based amyloid‐positivity. Baseline clinical and biological data, including magnetic resonance imaging (MRI), as well as longitudinal cognitive data of participants fulfilling criteria of stage 2 (SCD and amyloid positivity) will be presented in comparison with data of control subjects, amyloid negative SCD participants, participants with mild cognitive impairment (MCI) and with mild AD dementia. Conclusion Stage 2 of AD may be a future target for early treatment. SCD may serve as a clinical indicator of stage 2. DELCODE and other memory clinic‐based studies provide the basis to understand the potential usefulness of stage 2 in clinical trials and clinical practice in the future.